找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Handbook of Chronic Myeloid Leukemia; Timothy P Hughes,David M Ross,Junia V Melo Book 2014 Springer International Publishing Switzerland 2

[復(fù)制鏈接]
查看: 45444|回復(fù): 37
樓主
發(fā)表于 2025-3-21 18:23:40 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Handbook of Chronic Myeloid Leukemia
編輯Timothy P Hughes,David M Ross,Junia V Melo
視頻videohttp://file.papertrans.cn/421/420990/420990.mp4
概述A small practical pocketbook that provides hematologists, oncologists, pathologists and other healthcare providers involved in the diagnosis and treatment of CML with a concise and up-to-date survey o
圖書封面Titlebook: Handbook of Chronic Myeloid Leukemia;  Timothy P Hughes,David M Ross,Junia V Melo Book 2014 Springer International Publishing Switzerland 2
描述This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality,?which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1.?The clinical outcome for patients with CML has changed dramatically in the past 15 years and?this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein.?A number of first-, second- and third-generation TKIs are now available for the?treatment of CML, although a number of treatment challenges remain, not least the
出版日期Book 2014
關(guān)鍵詞BCR-ABL signaling; Hematology; Leukemia; Tyrosine kinase inhibitors; pharmacotherapy
版次1
doihttps://doi.org/10.1007/978-3-319-08350-6
isbn_softcover978-3-319-08349-0
isbn_ebook978-3-319-08350-6
copyrightSpringer International Publishing Switzerland 2014
The information of publication is updating

書目名稱Handbook of Chronic Myeloid Leukemia影響因子(影響力)




書目名稱Handbook of Chronic Myeloid Leukemia影響因子(影響力)學(xué)科排名




書目名稱Handbook of Chronic Myeloid Leukemia網(wǎng)絡(luò)公開度




書目名稱Handbook of Chronic Myeloid Leukemia網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Handbook of Chronic Myeloid Leukemia被引頻次




書目名稱Handbook of Chronic Myeloid Leukemia被引頻次學(xué)科排名




書目名稱Handbook of Chronic Myeloid Leukemia年度引用




書目名稱Handbook of Chronic Myeloid Leukemia年度引用學(xué)科排名




書目名稱Handbook of Chronic Myeloid Leukemia讀者反饋




書目名稱Handbook of Chronic Myeloid Leukemia讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:46:18 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:43:55 | 只看該作者
Book 2014d provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people)
地板
發(fā)表于 2025-3-22 06:58:29 | 只看該作者
5#
發(fā)表于 2025-3-22 09:55:24 | 只看該作者
6#
發(fā)表于 2025-3-22 15:50:13 | 只看該作者
7#
發(fā)表于 2025-3-22 17:31:33 | 只看該作者
8#
發(fā)表于 2025-3-23 01:08:06 | 只看該作者
9#
發(fā)表于 2025-3-23 02:55:35 | 只看該作者
Fiction: A Screenplay-to-Understanding,When a patient presents with suspected chronic myeloid leukemia (CML) appropriate assessments are needed to confirm the diagnosis and stage of disease, and to assign a risk score to that patient.
10#
發(fā)表于 2025-3-23 08:51:44 | 只看該作者
A Brief Note on Looking Forward,Resistance to tyrosine kinase inhibitors (TKIs) can be defined on the basis of its time of onset. Primary resistance is a failure to achieve a significant therapeutic response, whereas secondary or acquired resistance is the progressive reappearance of the leukemic clone after an initial response to the drug.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 02:52
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
喀什市| 惠来县| 保德县| 封丘县| 芦溪县| 拜城县| 都安| 鞍山市| 诸暨市| 安福县| 和平县| 荆门市| 仁化县| 淮南市| 定州市| 仁怀市| 高要市| 富裕县| 雅安市| 郑州市| 乐亭县| 铜梁县| 盘山县| 秭归县| 明水县| 洪雅县| 彰化市| 昭平县| 大英县| SHOW| 嘉定区| 盱眙县| 马鞍山市| 望城县| 日土县| 东乡族自治县| 永修县| 阜阳市| 滨海县| 玉屏| 柯坪县|